{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277468","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.029542+00:00","generated_at":"2026-05-16T21:15:52.240514+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cue Biopharma Q3 net loss $0.07/sh; ImmunoScape deal $15M upfront; new CEO","bullets":["Q3 net loss $7.45M ($0.07 EPS); revenue $2.15M (down 36% YoY); cash $11.7M (down 48% from Dec 2024).","Collaboration with ImmunoScape: upfront total $15M ($10M in Q4 2025, $5M in Nov 2026) plus 40% equity stake.","Usman Azam appointed President & CEO effective Sep 29; leadership transition to advance autoimmune asset CUE-401.","CUE-101+pembrolizumab in HPV+ HNSCC: 50% ORR, 88% 12-month OS, median OS 32.7 months.","R&D spend $4.8M (down 49% YoY); G&A $4.9M (up 72% YoY) due to severance and professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277468","json":"https://secwatch.observer/filing/0001193125-25-277468.json","markdown":"https://secwatch.observer/filing/0001193125-25-277468.md","text":"https://secwatch.observer/filing/0001193125-25-277468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/0001193125-25-277468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/cue-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:15:52.240514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}